Trial Profile
Capecitabine and Oxaliplatin Alone or in Combination With Cetuximab as First-Line Treatment for Metastatic EGFR [epidermal growth factor receptor]-Positive Colorectal Cancer, A Randomized Multicenter Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 04 Jun 2012 Actual end date (1 Feb 2006) added as reported by ClinicalTrials.gov.
- 04 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2008 Results published in the Annals of Oncology.